Pauline Brice

TL;DR: Brentuximab vedotin is an antibody-drug conjugate composed of a humanized anti-CD30 IgG1 and of the anti-mitotic monomethyl auristatine E1 that has shown interest in the management of CD30-positive mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.

TL;DR: To minimise HSR to PLD, an initial reduced rate of infusion of 0.1-0.2 mg of PLD/min is warranted and alternative therapy must be privileged, and if necessary, careful re-challenge with PLD may be attempted, however relapse of HSR may occur.

TL;DR: The 5-year overall survival and progression-free survival were 78% and 65% for DLBCL, and 60% and 48% for indolent lymphomas, respectively, and Adverse prognostic factors were male sex, poor performance status, elevated lactate dehydrogenase and high age-adjusted international prognostic index.

TL;DR: Crizotinib proved well tolerated and able to induce durable objective responses in most ALCL pts and was well tolerated with 5 grade (gr) ≥ 3 AEs; one patient with gr 3 hematological toxicities and one patientwith gr 3 cytolysis.

TL;DR: Patients who received vinblastine as single-agent chemotherapy for relapsing multifocal C-ALCL, a rare primary cutaneous CD30+ T-cell lymphoproliferative disorder, report on the effectiveness and therapeutic recommendations lacking for patients with methotrexate failure.